

PRESS RELEASE

ANTARES VISION CLOSES 2019 WITH RESULTS RISING SHARPLY BOARD BEGINS ACTIVITIES FOR TRANSITION TO THE MAIN STOCK MARKET

Main pro-forma consolidated results

- **Value of Production: EUR 149.5 million, +28.7% (2018: EUR 116.1 million)**
- **EBITDA: EUR 36.0 million, +22.7% (2018: EUR 29.3 million)**
- **EBIT: EUR 33.6 million, +17.7% (2018: EUR 28.6 million)**
- **Net Profit: EUR 25.3 million, +27.9% (2018: EUR 19.7 million)**
- **NFP*: positive by EUR 14.7 million (2018: positive by EUR 30.3 million)**

*adjusted for the effect of mark-to-market valuation of warrants and derivatives

Travagliato (BS), 20 April 2020 – Today Antares Vision Board of Directors approved the consolidated financial statement prepared according to the IFRS [International Financial Reporting Standards] and the draft financial statement of Antares Vision S.p.A. as at 31st December 2019, prepared according to the Italian accounting standards.

Emidio Zorzella, Chairman and Managing Director: *"For our Group, 2019 represented a turning point, with the listing on the AIM Italia market through the Business Combination with the SPAC Alp.I, a transaction that brought in resources worth EUR 50 million to strengthen the industrial growth and development of Antares Vision. This year, Antares Vision continued its commitment to develop its core business in the supply of Inspection, Track & Trace, and Smart Data Management solutions for the pharmaceutical sector and for all the most demanding sectors. We also consolidated our international presence by setting up new branches, while the investments plan, aimed at diversifying the business, continued with strategic acquisitions and the expansion of Antares Vision systems also in the food & beverage sector is now concretely underway. In September 2019 we bought 100% of FT System S.r.l. ("FT System"), one of the world leaders in inspection systems for the beverage and food sector, which counts the major multinationals of the sector among its more than 2,000 customers, whereas in December we bought 37.5% of Orobix, a transaction that will allow us to strengthen our positioning in smart data management and boost the activities of R&D and of the Innovation Centre.*

In light of the international context generated by the Covid-19 health emergency, Antares Vision believes it is more relevant and urgent than ever to ensure the TRUSTPARENCY™ of production processes around the world, increasing the use of technology to guarantee the distribution of safer, traceable and origin-certified products. Over the course of 2020, taking advantage of the slower rate of activities due to the global impact of Covid-19, Antares Vision will intensify its efforts to complete new strategic acquisitions and to accelerate the development of new technological solutions (first and foremost the traceability platform for the Agri-Food sector, stemming from our experience in the pharmaceutical field, also benefiting from funding from MISE [Ministry of Economic Development], so as to make it available as of 2021 for pilot projects supporting products Made in Italy). Antares Vision will also intensify the strengthening of its organisational structure, through the implementation of professional and managerial education plans, designed for the entire work force (associates, managerial staff and executives) and the analysis of all processes, to streamline times and costs. After the transition to the IFRS, Antares Vision starts adjusting its company processes to be ready to transition to the main market"

Main pro-forma consolidated results as at 31st December 2019

The consolidated financial statement as at 31st December 2019 is the first to be prepared according to the IFRS and embodies further compliance with the best practices of disclosure and transparency in view of possibly

PRESS RELEASE

applying for admission to the main Italian Stock Market in the future. Below are the pro-forma consolidated results with comments, in addition to the consolidated results, in which the income statement consolidates subsidiary FT System, acquired on 30th September 2019 as though it were acquired on 1st January 2019. Also note that the data were adjusted for some extraordinary entries, reclassified under the Operating Profit, for EUR 3.1 million overall.

The **pro-forma Value of Production**, equal to **EUR 149.5 million**, records an **increase of +28.7%** in comparison to EUR 116.1 million in 2018, **attributable to both organic growth and the acquisition of FT System**, which represented a highly significant step towards diversification in the extra-pharmaceutical sectors. Actually, FT System is one of the world leaders in inspection systems for the food and beverage sector, counting the biggest multinationals in the sector among its more than 2,000 customers. Considering only 3 months of FT System consolidation ("3-month FTS Financial Statement"), the Value of Production is equal to EUR 128.8 million, +10.9% on 2018.

The **pro-forma Gross Contribution Margin** stands at EUR 103.1 million, +42.3% in comparison to EUR 72.4 million in 2018, with an incidence on turnover of 72.2% (63.7% in 2018). The **pro-forma Added Value** is equal to EUR 78.1 million, +40.8% in comparison to EUR 55.4 million in 2018, with an incidence on turnover of 54.7% (48.7% in 2018). The significant improvement of both indicators is attributable, in addition to the acquisition of FT System, to the continuing increase of the turnover rate generated by software and especially by the after-sales assistance activities, that benefit from higher margins than the *hardware* solutions. The combined effect of the two elements has more than offset the higher cost of personnel, in line with the recruiting policy implemented in order to provide the Group with the necessary human resources to face the expected growth in coming years. The increase in human resources should, therefore, be considered as a planned investment for the future, aimed at implementing the strategy of Antares Vision.

The Gross Contribution Margin of the FTS 3-month Financial Statement is equal to EUR 89.6 million (+23.8% in comparison to 2018), while the Added Value is equal to EUR 68.1 million (+22.8% in comparison to 2018).

This dynamic translates into a **pro-forma EBITDA** of EUR 36.0 million, an increase of +22.7% in comparison to EUR 29.3 million in 2018, with an incidence on turnover of 25.2% (25.8% in 2018). The EBITDA of the FTS 3-month Financial Statement is EUR 31.5 million, +7.4% in comparison to 2018.

The **pro forma EBIT** amounts to EUR 33.6 million, up 17.7% in comparison to EUR 28.6 million in 2018, with an incidence on turnover of 23.6% (25.1% in 2018); the increase is less marked than the EBITDA growth, following higher amortisations, stemming from capitalisations carried out from the second semester of 2018 onwards. The EBIT of the FTS 3-month Financial Statement is EUR 29.4 million, +3.0% in comparison to 2018.

The lower marginality, in addition to being due to the effect of higher amortisations linked to the capitalisation of the development costs, is linked to FT System; nevertheless the Company believes that the integration of the offered solutions and the introduction of traceability systems and smart data management in FT System product offering will make it possible to eliminate the gap in marginality between FT System and Antares Vision, which is between 500bps and 600bps.

It should also be noted that the data were adjusted for **some extraordinary entries for EUR 3.1 million overall**, reclassified under EBIT and made up of costs linked to the listing (EUR 1,464 thousand), to the acquisitions completed during the year (EUR 575 thousand), to the mark-to-market valuation of the derivative instruments (EUR 570 thousand) and to the balance of extraordinary proceeds and expenses (EUR 467 thousand).

PRESS RELEASE

The **pro-forma Pre-Tax Income** amounts to EUR 33.6 million, +23.3% in comparison to EUR 27.2 million in 2018, with an incidence on turnover of 23.5% (23.9% in 2018). The Pre-tax Income of the FTS 3-month Financial Statement amounts to EUR 29.2 million, +7.4% in comparison to 2018.

The **pro-forma Net Income** is EUR 25.3 million, +27.9% in comparison to EUR 19.7 million in 2018, with an incidence on turnover of 18.0% (17.3% in 2018). The figures are partly influenced by the extraordinary entries, by the (positive) effect of the mark-to-market valuation of warrants issued with the Business Combination with Alp.I for a value of EUR 4,536 thousand (IAS 32) and by the (negative) effect of the valuation of Alp.I assets at fair value (IFRS 2) for a value of EUR 1,000 thousand. The Adjusted Net Income for extraordinary entries (net of the relative theoretical fiscal effect) and the effect of warrants and of the fair value of the Alp.I assets (fiscally exempt in the consolidated statement) is equal to EUR 23.9 million, +21.3% in comparison to 2018.

The Net Income of the FTS 3-month Financial Statement is EUR 22.1 million, +11.9% in comparison to 2018. The Adjusted Net Income is EUR 20.8 million, +5.2% in comparison to 2018.

The **Shareholders' Equity** is EUR 117.7 million, significantly improving in comparison to EUR 52.7 million in 2018; in addition to 2019 profit, this also benefits from the equity resources deriving from the Business Combination with Alp.I, and reflects the equity adjustments (negative by EUR 43.9 million) stemming from the adoption of IFRS.

The **Net Financial Position** (adjusted for the effect stemming from the mark-to-market valuation of warrants, as it will never lead to a financial cash-out) is **positive by EUR 15.3 million** (positive by EUR 14.7 million if the mark-to-market valuation of derivatives is taken into account), in comparison to **the positive value of EUR 30.4 million** (positive by EUR 30.3 million if the mark-to-market valuation of derivatives is taken into account) for 2018 (figures recalculated to neutralise the effect of the Horizon 2020 non-refundable loan which, although partially issued in 2018, had initially been booked under payables and not under contributions to operating expenses until the definitive certification was obtained from the issuing body over the course of 2019).

The change is mainly linked, on the one hand, to the positive operating cash flow and to the EUR 50 million capital increase following the Business Combination with Alp.I and, on the other hand, to the cash-out for the acquisitions of 100% of FT System for an overall disbursement of EUR 67.7 million (including approximately EUR 8 million of net cash), 37.5% of Orobix for a disbursement of EUR 3.25 million, and 51% of T2 Software S.A. for a disbursement of EUR 0.5 million. In addition, there are the tangible investments (mainly for expanding the production facilities in Italy), intangible investments (development cost capitalisations) and investments in subsidiaries (to open branches in Russia, India and Hong Kong).

Lastly, it should be noted that, over the course of the second semester of 2019, approximately EUR 77 million of cash resources were collected by obtaining medium/long-term loans, negotiated with primary credit institutions at particularly favourable conditions (average cost of 0.8% after taxes, without guarantees and with minimum covenants), thanks to the Company's excellent credit rating. These cash resources were partially collected to fund the acquisition of FT System and partially for possible future acquisitions. The balance sheet shows gross cash resources of almost EUR 120 million, increased in March 2020 to EUR 160 million, again thanks to new loans with similar conditions to those raised in 2019.

Proposed allocation of the net profit

The Board of Directors resolved to recommend the Shareholders' Meeting to allocate the net profit of the Parent Company equal to EUR 19,277,983, for an amount of EUR 977,803 (equal to the revaluation of the shareholding in the subsidiary Imago Technologies GmbH) to the revaluation reserve pursuant to art. 2426 of the Italian Civil Code and the entire remaining amount of EUR 18,300,180 to the extraordinary reserve.

PRESS RELEASE

Significant events of the year

One of the most significant events of 2019 was certainly the Business Combination between the parent company Antares Vision S.p.A. and Alp.I S.p.A., a SPAC promoted by Mediobanca along with other promoters from the financial world. This transaction brought EUR 50 million to Antares Vision intended to finance its industrial growth and development and it led the Company to be listed on the AIM Italia market as of 18th April 2019, thereby obtaining greater visibility, reliability and credibility in relation to all stakeholders.

Antares Vision further consolidated its presence on foreign markets, not only through existing branches, but also by setting up new branches.

- On 12th April 2019, Antares Vision Rus O.O.O. was founded, 100% controlled by Antares Vision S.p.A. to exploit the new business opportunities offered by the new traceability standards issued by the Russian government, related to a wide range of consumer products.
- On 20th April 2019, Antares Vision India Private Limited was founded, following the completion of a joint venture with Indian company Jay Instruments and Systems Private Limited. Although Antares Vision S.p.A. holds 51% of the share capital, it should be noted that in the consolidated Financial Statement the shareholding was valued according to the Equity Method due to the presence of shareholders' agreements which result in joint control.
- On 22nd August 2019, a new branch, Antares Vision Asia Pacific Limited, was set up in Hong Kong. The company, governed by Hong Kong law, is fully controlled by Antares Vision S.p.A.. Setting up Antares Vision Asia Pacific will make it possible to establish a presence on the Chinese market and growing countries in Asia, through a direct presence in the area, exploiting the strong growth potential of inspection systems and tracking solutions in various target sectors, including the pharmaceutical and food & beverage sectors. On 27th January 2020, the incorporation of a Chinese branch, which will be located in the city of Shenzhen, was approved.
- On 13th September 2019, through a share capital increase, subsidiary Antares Vision do Brasil bought 51% of T2 Software S.A., a Brazilian company specialised in solutions for smart data management to maximise production performance.

Furthermore, in 2019 the company continued pursuing the investments plan for the strategic diversification of the business.

- Indeed, on 30th September 2019, 100% of FT System S.r.l. was acquired (and indirectly of its subsidiaries in France and the United States), specialised in testing and inspection technologies mainly for bottling in the beverage and food industry.
- In December 2019, through a EUR 3.25 million capital increase, Antares Vision acquired a 37.5% share of the capital of Orobix S.r.l., which operates in artificial intelligence services. At the same time a shareholders' agreement was signed with the majority shareholder, Girolamo Initiatives S.r.l., which envisages, in favour of Antares Vision, incremental acquisition options to be exercised within pre-set time-frames (from 30th June 2023 and from 30th June 2025) for 30% of the Orobix share capital overall. The resources provided through the capital increase will be used to support the development plans, which are aimed at making Orobix one of the top leading AI Service Companies. At the same time, the acquisition will allow Antares Vision to strengthen its position in smart data management, thanks to the experience gained by the Bergamo-based company, and to boost the activities of R&D and of its Innovation Centre.

Significant events following the end of the fiscal year and business outlook

The first months of 2020 were characterised by the health emergency linked to the spread of Covid-19. Management monitored the evolving situation closely and implemented all the guidelines issued by the

PRESS RELEASE

Competent authorities with the utmost promptness and accuracy. The health and wellbeing of employees, associates and partners were prioritised by adopting protection and prevention measures, such as switching to smart-working, organising video conferences in place of meetings, carefully managing production and installation activities, in accordance with the safety directives.

As for the Parent Company, the Decree of the (It.) Prime Minister of March 22nd, 2020 classified Antares Vision and FT System as essential businesses, thereby not requiring their operations to be suspended. Antares Vision was more than pleased with this choice. The pharmaceutical industry sector, the main target sector for Antares Vision, now together with the beverage sector, was and is under pressure during this emergency and in many cases it has called for the activation of task forces and continuous cycle productions. In such a situation it is essential for Antares Vision to guarantee the continuity of supplies and services provided to customers, although with testing and technical assistance operations carried out remotely.

Today Antares Vision and its management remain vigilant; yet, although the current situation will inevitably have a negative impact on the delivery and installation times of the solutions offered and, thereby, will delay revenue, and although it is premature to be making reasonably plausible forecasts of the impact that this health emergency will have on the entire economic system, in Italy and the world, it is certain that this event will drive the sense of urgency to implement strict standards and regulations that strengthen and guarantee the safety of the people, also in relation to the quality, originality and sustainability of essential products, such as medicines, foods, beverages, cosmetics. For this reason, Antares Vision has passionately and wholeheartedly adhered to the initiative "Innovate for Italy", launched by the Ministry of Health, by the National Institute of Health, and by the World Health Organisation, proving that it is ready to place its skills and expertise at the service of the scientific community and the entire population.

At this time of uncertainty, Antares Vision's commitment to safety and health is unwavering, combining the three macro business areas: inspection, traceability and smart data management.

The inspection systems guarantee total quality control for product integrity. Track & Trace is the tool to follow every product from its origin throughout the production process, along the entire value chain, all the way to the end consumer. The combination of both technologies and the implementation of a single smart data management system that combines traceability and inspection functions, is the strategy for guaranteeing product safety and transparency of the supply chain, fighting counterfeiting, preserving the reputation of the trademark, managing any faulty product recalls thoroughly and promptly, and establishing a relationship with the end consumer based on trust.

This is the background to the agreement signed on 10th April 2020 to buy 82.83% of Tradeticity d.o.o., with a call option to buy the remaining 17.17% after the approval of the financial statement as at 31st December 2021. Tradeticity, a company founded in Zagreb in 2017 and specialised in the software management of advanced traceability and serialisation processes, has consolidated expertise and market shares in the pharmaceutical industry, operating on both the domestic and international market. The acquisition, which will entail a cash disbursement of approximately EUR 1,040 thousand, is planned to close by mid May 2020 at the latest, when certain conditions precedent are completed and it will allow Antares Vision to extend its geographical presence to Eastern Europe, increasing market penetration and boosting the creation and implementation of tracking and serialisation solutions along the entire pharmaceutical supply chain.

To be in a position to seize all future challenges, Antares Vision will also be able to rely on the strategic potential of Orobix, to increase the value of its offer on the market and fully exploit artificial intelligence applications in all sectors, for both data analysis and image analysis for quality control. Today, artificial intelligence systems play a crucial role in the digital transformation process of businesses and offer a significant competitive advantage on the market.

Start-up of the activities to transition to the main Stock Market - STAR Segment [high performance equities segment]

PRESS RELEASE

In keeping with the project that began with the merger with ALP.I S.p.A. signed on 15th April 2019, the Board of Directors examined the project involving the possible transition to trading ordinary shares and warrants of the Company on the Screen-Based Trading System, possibly the 'STAR' high performance equities segment. The transfer to the main market would assure to the Company greater financial visibility (with strategic partners as well as institutional investors) in line with the hopes of Antares Vision, as well as a better valuation of the security, thanks to the entry into a regulated market, to the greater floating capital and therefore greater liquidity in comparison to AIM Italia.

For the transition to the main stock market - subject to the stock market contingent conditions – the Board of Directors decided to start the preparatory activities for listing and, therefore, to proceed with appointing the Sponsor and identifying the Advisors who will support the Company throughout the process.

The detailed information on the terms and conditions of the listing will be disclosed according to the time frames and methods set forth by the regulations in force.

Stock option plan reserved to executive directors and employees - Proxy for the increase of share capital

The Company's Board of Directors decided to approve the guidelines of a share-based incentive plan called "2020-2022 Stock Option Plan" (the "**Plan**"), to be implemented through the free allocation of a maximum of 1,000,000 options (the "**Options**") for the subscription and/or allocation on payment of ordinary shares of the Company to the executive directors and key employees of the Company and of the Group. The purpose of the Plan is to secure a relationship of compensation in line with national and international best practices, increasing the already significant level of company retention for human resources considered key to the Company, by planning medium/long-term objectives aimed at improving the performance of the Company and the Group under the banner of gradual and increasing creation of value, set to translate into a direct benefit for shareholders.

The Plan envisages, *inter alia*, that the Options:

- a) will confer to each beneficiary the right to subscribe to newly-issued shares, or to acquire shares held in the Company portfolio, against payment of a preset price;
- b) will mature, in whole or in part, in a preset period of time, on the condition that the beneficiaries have reached certain objectives, which will be identified in detail by the Board of Directors;
- c) may be exercised by the respective beneficiary only after a certain period of time has elapsed from their maturity.

When the Options are exercised, the corresponding shares will be subscribed and/or purchased, as the case may be, against payment of a price set by the Board of Directors taking into account the average closing price in the month prior to the date of allocation of the Options.

The main conditions and methods for implementing the Plan, and for the Options to be allocated, mature and be exercised will be indicated in the explanatory report to the items on the agenda of the Shareholders' Meeting to be drafted by the Board of Directors and to be published within the deadlines laid down by law, as well as in the document "Plan Guidelines", to be attached to said report.

For the implementation and execution of the Plan, the Board of Directors has decided to submit to the Shareholders' Meeting, subsequently to the approval of said Plan, the proposal to grant appropriate powers to the Board of Directors, to be exercised in compliance with the principles and criteria set forth in the Plan Guidelines.

The Board of Directors also decided to submit to the Shareholders' Meeting the recommendation that the Board be granted, pursuant to article 2443 of the Italian Civil Code, for a period of five years from the date on which the Meeting will adopt the resolution, the right to increase the Company's share capital, in separate issues and with exclusion of pre-emptive rights pursuant to article 2441, paragraphs 5 and 8, of the Italian Civil Code, by a

PRESS RELEASE

maximum nominal amount of EUR 2,400 (in addition to the share premium), through the issue, even in more than one instalments, of a maximum of 1,000,000 ordinary shares.

Said capital increase and the shares deriving therefrom will be intended solely to service the stock option plan called "2020-2022 Stock Option Plan" (which will be submitted for approval to the Ordinary Shareholders' Meeting, as per above) and will be offered for subscription to the executive directors and to the employees of the Company and/or the Group to be identified by the Board of Directors.

In exercising the proxy for the share capital increase, the Board of Directors will set, each time, the number of shares to be issued and their price, having taken into account the arithmetical average of the closing prices of the average of the closing prices in the last month prior to the date of Option allocation.

Proposal for authorisation to purchase and sell own shares

The Board of Directors decided to submit for the Shareholders' Meeting's approval the authorisation to purchase ordinary shares of the Company, in one or more instalments, to an extent to be set by the Board of Directors at its discretion, up to a maximum number that may not exceed 2% of the share capital.

The proposal states that the purchase may be made, at intervals deemed suitable and, in any case, within 18 months from the date of the Shareholders' Meeting's resolution, for a unit price that may not be lower than a minimum of 10% and no higher than a maximum of 10% of the reference price recorded by the share on the Stock Exchange session on the day preceding each individual transaction.

The purchase transactions must comply with the methods set forth by the *pro tempore* regulatory framework in force and with accepted market practices. Own shares must, in any case, be purchased so as to guarantee equality of treatment among the Shareholders.

The request for authorisation also refers to the sale of own shares. In this regard, it should be noted that the own shares may be allocated to directors and/or employees of the Company or of Group companies in accordance with incentive plans based on Antares Vision shares, including the stock option plan called "2020-2022 Stock Option Plan" which, as mentioned earlier, will be subject to the Shareholders' Meeting's approval.

It should be pointed out that, to date, the Company does not hold own shares.

Appointment of the Remuneration Committee

The Board of Directors decided to establish an internal remuneration committee. The committee will be composed of three members, all non-executive, two of whom will meet the independence requirements referred to in art. 148, paragraph 3 of (It.) Legislative Decree 58/1998; the persons appointed are Prof. Marco Vitale, as Chairman, Prof. Dante Roscini and Mr. Massimo Perona.

The remuneration committee will remain in office until the expiration date foreseen for the Board of Directors, or until the approval of the financial statement of the fiscal year that will end on 31st December 2021.

The CVs of the committee's members will be available on the Company's website at the address www.antaresvision.com, in the section "Investors - Governance - Structure - in-Board committees".

Proposal for the increase of the number of directors from the current 7 to 9 and for filling the vacancy in the Board of Statutory Auditors

The Board of Directors decided to submit to the Shareholders' Meeting's approval the proposal to increase the number of members of the Board of Directors from the current 7 (seven) to 9 (nine), with the aim of increasing the integration of the management body's skills in line with the Company's constant evolution, also as a result of the acquisition of FT System.

The increase of the number of Board members and the appointment of two new Directors was assessed by the management body as appropriate in order to acquire additional professional skills without losing those that are

PRESS RELEASE

already represented in the management body, in light of the growing operational complexity in support of the Company and the Group's growth plans.

The Board of Directors also decided – acknowledging the resignation, on professional grounds, of the statutory auditor Mr Paolo Prandi as of the date of the Shareholders' Meeting approving the financial statement as at 31st December 2019 – to recommend to the Shareholders' Meeting to fill the vacancy in the Board of Statutory Auditors by appointing a new statutory auditor.

Calling of the ordinary and extraordinary meeting

The Board of Directors decided to convene the ordinary and extraordinary Shareholders' Meeting of the Company on 20th May 2020 and, if necessary, on second call on 21st May 2020. The call convening the shareholders' meeting will be published on the Company's website www.antaresvision.com and on the "Italia Oggi" daily, and disseminated via the "1Info SDIR" advertising system in the time frames and according to the methods set out by the law and regulations in force.

The documentation relating to the items on the agenda will be made available to the public at the company's registered office and on the website www.antaresvision.com within the deadlines laid down by the regulatory framework in force.

Antares Vision, a company listed on AIM Italia through a business combination with ALP.I, a SPAC promoted by Mediobanca, is a world leader in systems for quality control, tracking solutions to fight counterfeiting and control of the supply chain, and smart data management, in all the most demanding industrial sectors, from pharmaceuticals to biomedical devices, from food and beverage to cosmetics and fashion. It operates in over 60 countries around the world, with 4 offices in Italy, 11 offices abroad, 2 innovation and research centres in Italy and Ireland, and a network comprising over 30 partners worldwide. With 20 years of experience in vision technologies, Antares Vision supplies 10 of the world's 20 leading pharmaceutical companies: over 25,000 inspection systems guarantee product safety and quality each day, while 6,500 inspection tests and over 3,500 serialisation lines installed all over the world guarantee the traceability of over 5 billion products throughout the entire distribution chain. With the aim to continue supporting the growth and development strategy, in 2019 shareholding agreements were stipulated with T2 Software, a Brazilian software company, and Orobix, Italian leader in artificial intelligence services. Antares Vision acquired 100% of FT System, a leader in control and inspection in the beverage sector.